NVAX Novavax Inc

Price (delayed)

$51.63

Market cap

$4.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.71

Enterprise value

$2.89B

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
The revenue has soared by 53% YoY and by 22% from the previous quarter
NVAX's gross profit has soared by 51% YoY and by 21% QoQ
Novavax's equity has surged by 119% QoQ but it has shrunk by 94% YoY
Novavax's net income has plunged by 114% YoY but it has increased by 24% from the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
78.13M
Market cap
$4.03B
Enterprise value
$2.89B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
60.29
Price to sales (P/S)
2.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
Earnings
Revenue
$1.4B
EBIT
-$1.27B
EBITDA
-$1.11B
Free cash flow
-$489.18M
Per share
EPS
-$17.71
Free cash flow per share
-$6.4
Book value per share
$0.86
Revenue per share
$18.35
TBVPS
$35.31
Balance sheet
Total assets
$2.83B
Total liabilities
$2.77B
Debt
$440.5M
Equity
$65.32M
Working capital
$86.4M
Liquidity
Debt to equity
6.74
Current ratio
1.04
Quick ratio
0.91
Net debt/EBITDA
1.03
Margins
EBITDA margin
-78.9%
Gross margin
98.9%
Net margin
-93.9%
Operating margin
-90.4%
Efficiency
Return on assets
-49.1%
Return on equity
-572.5%
Return on invested capital
N/A
Return on capital employed
-220.9%
Return on sales
-90.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-0.35%
1 week
28.31%
1 month
10.94%
1 year
-73.18%
YTD
-63.91%
QTD
-29.9%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.4B
Gross profit
$1.39B
Operating income
-$1.27B
Net income
-$1.32B
Gross margin
98.9%
Net margin
-93.9%
Novavax's net income has plunged by 114% YoY but it has increased by 24% from the previous quarter
Novavax's operating income has plunged by 111% YoY but it has increased by 25% from the previous quarter
The revenue has soared by 53% YoY and by 22% from the previous quarter
NVAX's gross profit has soared by 51% YoY and by 21% QoQ

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
60.29
P/S
2.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
Novavax's EPS has shrunk by 88% YoY but it has increased by 24% QoQ
Novavax's equity has surged by 119% QoQ but it has shrunk by 94% YoY
NVAX's P/S is 85% below its 5-year quarterly average of 18.5 and 72% below its last 4 quarters average of 9.9
The revenue has soared by 53% YoY and by 22% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on equity has shrunk by 55% QoQ
Novavax's return on sales has decreased by 39% YoY but it has increased by 39% QoQ
NVAX's return on assets is up by 26% since the previous quarter but it is down by 21% year-on-year

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 2.4% higher than its total liabilities
The total liabilities has soared by 76% year-on-year but it has declined by 5% since the previous quarter
NVAX's quick ratio is down by 49% year-on-year but it is up by 10% since the previous quarter
Novavax's equity has surged by 119% QoQ but it has shrunk by 94% YoY
Novavax's debt has decreased by 4.3% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.